Literature DB >> 2187963

Zidovudine prophylaxis following exposure to human immunodeficiency virus.

R A Miller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2187963     DOI： 10.1007/bf02600547

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  8 in total

1.  Prophylactically administered Retrovir in health care workers potentially exposed to the human immunodeficiency virus.

Authors:  S W LaFon; S N Lehrman; D W Barry
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

Review 2.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

Authors:  R Yarchoan; H Mitsuya; C E Myers; S Broder
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

3.  3'-Azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS.

Authors:  L Tavares; C Roneker; K Johnston; S N Lehrman; F de Noronha
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

4.  Frequent isolation of HIV-1 from the blood of patients receiving zidovudine (AZT) therapy.

Authors:  D S Burke; R R Redfield; D C Bjornson; A K Fowler; C N Oster
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

5.  Zidovudine prophylaxis for needlestick exposure to human immunodeficiency virus: a decision analysis.

Authors:  H S Sacks; D N Rose
Journal:  J Gen Intern Med       Date:  1990 Mar-Apr       Impact factor: 5.128

6.  Toxicity and efficacy of 2',3'-dideoxycytidine in clinical trials of pigtailed macaques infected with simian retrovirus type 2.

Authors:  C C Tsai; K E Follis; M Yarnall; G A Blakley
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine.

Authors:  R M Ruprecht; L G O'Brien; L D Rossoni; S Nusinoff-Lehrman
Journal:  Nature       Date:  1986 Oct 2-8       Impact factor: 49.962

8.  Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis.

Authors:  D K Henderson; J L Gerberding
Journal:  J Infect Dis       Date:  1989-08       Impact factor: 5.226
  8 in total
  1 in total

1.  Differential antiviral activities and intracellular metabolism of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine in human cells.

Authors:  E Mukherji; J L Au; L E Mathes
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.